Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | OGA | O60502 | 1/20 | 0.47 |
| ▸ | HEXA | P06865 | 1/20 | 0.47 |
| ▸ | HEXB | P07686 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30793979 | 0.89 | GLS (0.50) | GLSMAOBOGAHEXAHEXB | |
| SCHEMBL10681723 | 0.82 | CES1 (0.65) | MAOBALDH1A1 | |
| SCHEMBL8489619 | 0.82 | CA12 (0.47) | CASP3 | |
| SCHEMBL12612148 | 0.81 | RPS6KA2 (0.54) | GLSCASP3ALDH1A1 | |
| SCHEMBL3186901 | 0.80 | KMT2A (0.48) | MAOBCASP3ALDH1A1 | |
| SCHEMBL3186877 | 0.80 | KMT2A (0.48) | MAOBCASP3ALDH1A1 | |
| SCHEMBL4388842 | 0.79 | GLS (0.55) | GLSOGAHEXAHEXB | |
| SCHEMBL30839867 | 0.79 | GLS (0.55) | GLSOGAHEXAHEXB | |
| SCHEMBL805142 | 0.79 | OGA (0.70) | GLSOGAHEXAHEXBCASP3 | |
| SCHEMBL5049343 | 0.79 | ALDH1A1 (0.48) | GLSMAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-3640248-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-04-22 | — | — | EP | disclosed |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-03-19 | — | — | US | disclosed |
| WO-2019164122-A1 | XANTHENE-BASED COMPOUND, COLORANT COMPOSITION, PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE MATERIAL, COLOR FILTER, AND DISPLAY DEVICE | 주식회사 엘지화학 | 2019-08-29 | — | — | WO | disclosed |
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1966210-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071393-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | GLS 241/4885MAOB 3308/4885OGA 2519/4885 |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | GLS 875/4885MAOB 2363/4885OGA 4691/4885 |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | GLS 875/4885MAOB 2363/4885OGA 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.